The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Jul 2017 07:00

RNS Number : 5054M
Silence Therapeutics PLC
31 July 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Silence Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 July 2017

6. Date on which issuer notified:

28 July 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 > 25,26

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B9GTXM62

17,458,481

17,458,481

18,838,695

18,838,695

26.92%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

18,838,695

26.92%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Blake Holdings Limited

7,550,731

Seren Investment Management Limited

8,223,507

Oak Trust Limited

182,837

Richard Griffiths - indirect holdings

692,153

Sarossa Plc

2,189,467

Total

18,838,695

 

 

The above undertakings are all controlled by Richard Griffiths

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+ 44 1534 719 761

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURSVRBRABOAR
Date   Source Headline
23rd Jul 20205:02 pmRNSResults of EGM
22nd Jul 20204:29 pmRNSHolding(s) in Company
22nd Jul 20204:24 pmRNSHolding(s) in Company
21st Jul 20207:00 amRNSSilence Therapeutics to Participate in Conferences
16th Jul 20207:00 amRNSMallinckrodt Exercise of Options
2nd Jul 202010:50 amRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCircular and notice of general meeting
30th Jun 202012:39 pmRNSHolding(s) in Company
29th Jun 20204:55 pmRNSHolding(s) in Company
23rd Jun 20207:00 amRNSBusiness Update
23rd Jun 20207:00 amRNSSubmission of Registration Statement to the US SEC
10th Jun 20205:58 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSResults of AGM
5th Jun 20204:33 pmRNSHolding(s) in Company
1st Jun 20204:19 pmRNSAdditional Listing
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:36 pmRNSPrice Monitoring Extension
29th May 20209:37 amRNSPDMR Shareholding
21st May 20204:28 pmRNSGrant of Share Options
20th May 20207:00 amRNSNASDAQ Intention to List
20th May 20207:00 amRNSBroker Appointment
20th May 20207:00 amRNSCompany Update
14th May 20207:00 amRNSParticipation at RBC Virtual Healthcare Conference
12th May 20204:12 pmRNSHolding(s) in Company
12th May 20209:30 amRNSPDMR Dealing
7th May 20207:00 amRNSNotice of AGM
20th Apr 20203:28 pmRNSAdditional listing – correction
20th Apr 20207:00 amRNSPDMR Dealing and Additional Listing
17th Apr 20209:34 amEQSEdison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
16th Apr 20207:00 amRNSSilence Therapeutics publication of Annual Report
14th Apr 20207:00 amRNSFinal results year ended 31 December 2019
9th Apr 20207:00 amRNSSilence Announces COVID-19 Partnership
2nd Apr 20207:00 amRNSPresentation at Conference and Notice of Results
1st Apr 20204:12 pmRNSAdditional Listing
31st Mar 202011:51 amRNSHolding(s) in Company
30th Mar 20203:00 pmRNSHolding(s) in Company
25th Mar 20202:56 pmEQSEdison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
25th Mar 20207:01 amRNSR&D Update
25th Mar 20207:00 amRNSCollaboration with AstraZeneca
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:36 pmRNSPrice Monitoring Extension
17th Mar 202012:07 pmRNSSecond Price Monitoring Extn
17th Mar 202012:02 pmRNSPrice Monitoring Extension
13th Mar 202012:07 pmRNSSecond Price Monitoring Extn
13th Mar 202012:02 pmRNSPrice Monitoring Extension
10th Mar 20201:23 pmRNSHolding(s) in Company
2nd Mar 202012:24 pmRNSHolding(s) in Company
19th Feb 20209:14 amRNSHolding(s) in Company
18th Feb 20207:03 amRNSSilence to Present at Cowen Health Care Conference
17th Feb 202010:00 amRNSSilence Launches Scientific Advisory Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.